N-acetyl-t-butoxysarcosine | 168553-60-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-acetyl-t-butoxysarcosine
• 英文别名: tert-butyl 2-(N-methylacetamido)acetate；tert-butyl 2-[acetyl(methyl)amino]acetate
• CAS: 168553-60-4
• 化学式: C₉H₁₇NO₃
• 分子量: 187.239
• InChiKey: HBOXCPCHNUKDJF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-acetyl-t-butoxysarcosine 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以100 mg的产率得到2-[乙酰基(甲基)氨基]乙酸
  参考文献：
  名称：

  N 端螺旋模板的最佳 N 帽：氢键效率和电荷变化的影响

  摘要：

  引入了一系列有效的螺旋起始 N 端帽 X-Hel，扩展了先前报告的构象模板 Ac-Hel 的范围和多功能性，（Kemp, DS; Allen, TJ; Oslick, SJ Am. Chem. Soc . 1995, 117, 6641-6657) 并且描述了基于结构特异性分子内氢键形成预测帽盖性能的工作原理。用氨基甲酸乙酯、尿素或磺酰胺替代 N-乙酰基会产生效率较低的多肽螺旋诱导剂。发现 N-甲酰基帽等同于 N-乙酰基，可以提供更方便的定量螺旋报告特性。衍生自系列 X = (-)O(2)C-(CH(2))(n)-CO, 0 < 或 = n < 或 = 3 的阴离子 N-帽优于 N-乙酰基，正如N-酰基甘氨酰和 N-酰基-β-天冬氨酰。后一对帽允许在多肽链内引入 X-Hel 功能，从而控制肽子序列的螺旋度。讨论了这些上限函数的应用。这项工作主要侧重于直接的实际目标，旨在提高水溶液中分离的中

  DOI：

  10.1021/ja010812a
• 作为产物：
  描述：

  溴乙酸叔丁酯 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 1.0h， 生成 N-acetyl-t-butoxysarcosine
  参考文献：
  名称：

  New prototypical O-linked-glycopeptidomimetics corresponding to the linkage region of proteoglycans

  摘要：

  A new class of glycopeptidomimetic composed of N-substituted oligoglycine (peptoid) mimicking the beta-D-Xyl-(1 --> 3)-O-L-Ser linkage region of proteoglycans was synthesized using a convergent approach. Reiterative N-alkylation-N-bromoacetylation reactions were used starting from tert-butyl bromoacetate (1) and isopropylamine. Perbenzoylated 2-aminoethyl beta-D-xylopyranoside 10 constituted the key glycan L-Ser mimic. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0008-6215(96)00301-1

文献信息

• Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use related applications
  申请人：NitroMed, Inc.

  公开号：US20040024057A1

  公开（公告）日：2004-02-05

  The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders.

  该发明描述了新型亚硝化非甾体抗炎药（NSAIDs）及其药用盐，以及包含至少一种亚硝化NSAID的新型组合物，以及可选地，至少一种提供、转移或释放一氧化氮、刺激内源性一氧化氮合成、提高内源性内皮源性舒张因子水平或是一氧化氮合酶底物的化合物，和/或至少一种治疗剂。该发明还提供了包含至少一种亚硝化NSAID和至少一种提供、转移或释放一氧化氮、提高内源性内皮源性舒张因子水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物和/或至少一种治疗剂的新型组合物。该发明还提供了包含至少一种亚硝化NSAID，可选地至少一种一氧化氮供体和/或至少一种治疗剂的新型试剂盒。该发明还提供了治疗炎症、疼痛和发热的方法；治疗胃肠道疾病的方法；促进伤口愈合的方法；治疗和/或预防由非甾体抗炎化合物使用引起的胃肠道、肾脏和/或呼吸道毒性的方法；治疗炎症性疾病状态和/或疾病的方法；以及治疗和/或预防眼科疾病和/或疾病的方法。
• Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
  申请人：Earl A. Richard

  公开号：US20050222243A1

  公开（公告）日：2005-10-06

  The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders.

  本发明描述了新型亚硝基化非甾体抗炎药（NSAIDs）及其药学上可接受的盐，以及包含至少一种亚硝基化NSAID和可选地至少一种化合物的新型组合物，该化合物捐赠、转移或释放一氧化氮，刺激内源性一氧化氮的合成，提高内源性的内皮源性舒张因子水平或是一氧化氮合酶的底物，和/或至少一种治疗剂。本发明还提供了包含至少一种亚硝基化NSAID和至少一种化合物的新型组合物，该化合物捐赠、转移或释放一氧化氮，提高内源性的内皮源性舒张因子水平，刺激内源性一氧化氮的合成或是一氧化氮合酶的底物和/或至少一种治疗剂。本发明还提供了包含至少一种亚硝基化NSAID、可选地至少一种一氧化氮供体和/或至少一种治疗剂的新型试剂盒。本发明还提供了治疗炎症、疼痛和发热的方法；治疗胃肠道疾病的方法；促进伤口愈合的方法；治疗和/或预防由非甾体抗炎化合物使用引起的胃肠道、肾脏和/或呼吸毒性的方法；治疗炎症性疾病状态和/或疾病的方法；以及治疗和/或预防眼科疾病和/或疾病的方法。
• First synthesis of N-linked-glycopeptoid as new glycopeptidomimetics
  作者：Uttam K. Saha、René Roy

  DOI：10.1016/0040-4039(95)00620-r

  日期：1995.5

  The first N-linked glycopeptoid containing N-acetylglucosaminide (D-GlcNAc) was synthesized using the oligo(N-substituted glycines) (NSGs) approach. The strategy presented herein offers the advantage of a convergent synthesis.
• ALIPHATIC NITROGENOUS FIVE-MEMBERED RING COMPOUNDS
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP1325910B1

  公开（公告）日：2008-09-17
• NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE
  申请人：Nitromed, Inc.

  公开号：EP1539729A2

  公开（公告）日：2005-06-15